Parexel International acquires clinical pharmacology units
US biopharmaceutical outsourcing company Parexel International Corporation has acquired 3ClinicalResearch (3C), a German clinical research organisation with expertise in Phase I and Phase IIa proof-of-concept studies.
US biopharmaceutical outsourcing company Parexel International Corporation has acquired 3ClinicalResearch (3C), a German clinical research organisation with expertise in Phase I and Phase IIa proof-of-concept studies.
The privately held company based in Berlin has Phase I/IIa facilities at the Charite University Hospital in Berlin and in Hennigsdorf, Germany, that add approximately 80 beds and two sleep research laboratories to Parexel's worldwide clinical pharmacology network.
Parexel has been affiliated with 3C for several years, having established a minority ownership stake in June of 2000. It acquired the remaining outstanding shares of 3C through a cash purchase of approximately $12m in March this year.
"The acquisition of 3C adds further capacity to our clinical pharmacology business and to our operations in Berlin. Furthermore, 3C's proof-of-concept capabilities help to round out our portfolio of services,' said Josef H. von Rickenbach, Parexel's chairman and ceo. 'Our enhanced clinical pharmacology network will provide us with access to a broader volunteer and patient population, and enable us to more efficiently recruit and screen patients for client studies.'